In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo

Bristol-Myers Squibb has lost yet more ground in its ongoing cancer immunotherapy battle with rival Merck.

Along with its earnings, the pharma firm reported Thursday that it has pulled a key approval application to use a combo regimen of its already approved immunotherapies, nivolumab (Opdivo) and ipilimumab (Yervoy), in a portion of patients with newly diagnosed, advanced non-small cell lung cancer (NSCLC).